RMCM
MRNA icon

Reynders McVeigh Capital Management’s Moderna MRNA Stock Holding History

Reynders McVeigh Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,903
Closed -$595K – 210
2024
Q3 		$595K Sell
8,903
-4,767
-35% -$438K 0.03% 134
2024
Q2 		$1.62M Buy
13,670
+618
+5% +$78.2K 0.09% 80
2024
Q1 		$1.39M Sell
13,052
-911
-7% -$91.8K 0.08% 81
2023
Q4 		$1.39M Buy
13,963
+3,588
+35% +$302K 0.09% 83
2023
Q3 		$1.07M Sell
10,375
-1,786
-15% -$199K 0.07% 89
2023
Q2 		$1.48M Sell
12,161
-1,807
-13% -$241K 0.1% 82
2023
Q1 		$2.15M Sell
13,968
-1,000
-7% -$165K 0.15% 66
2022
Q4 		$2.69M Sell
14,968
-1,792
-11% -$293K 0.2% 65
2022
Q3 		$1.98M Buy
16,760
+2,311
+16% +$351K 0.15% 67
2022
Q2 		$2.06M Buy
14,449
+351
+2% +$50.2K 0.15% 66
2022
Q1 		$2.43M Buy
14,098
+9,258
+191% +$1.56M 0.15% 65
2021
Q4 		$1.23M Buy
+4,840
New +$1.42M 0.07% 100

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Reynders McVeigh Capital Management's MRNA Position: Q4 2024 in Review

Reynders McVeigh Capital Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 8,903 shares — an estimated $595K sold.

Reynders McVeigh Capital Management first reported a position in MRNA in Q4 2021 and held it in 12 quarters. The position peaked at $2.69M in Q4 2022. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Reynders McVeigh Capital Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Reynders McVeigh Capital Management sold 8,903 Moderna shares in Q4 2024, an estimated $595K.
  • Reynders McVeigh Capital Management first reported a position in Moderna in Q4 2021 and held it in 12 quarters.
  • Reynders McVeigh Capital Management's Moderna position peaked at $2.69M in Q4 2022.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Reynders McVeigh Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.